Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ION269

Oligonucleotide (Antisense oligonucleotide) · Gene silencing · developed by IONIS PHARMACEUTICALS

Phase 1 Most advanced trial (none active)

IONS Developer

1 Registered trials

What is ION269?

ION269 is an antisense oligonucleotide administered by intrathecal injection. It is being studied in Alzheimer disease and Down syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (Antisense oligonucleotide)
Mechanism: Gene silencing
Therapy area: Neurology
Developer: IONIS PHARMACEUTICALS (IONS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06673069	Phase 1	Alzheimer Disease	Terminated	IONS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer DiseaseDown Syndrome

More from IONIS PHARMACEUTICALS

Donidalorsen FDA approved Olezarsen FDA approved Zilganersen FDA approved BIIB094 Phase 1 ION224 Phase 2 ION337 Phase 1/2 ION356 Phase 1 ION363 Phase 3 ION440 Phase 1/2 ION464 Phase 1 ION717 Phase 1/2 ION775 Phase 2

Sources

ClinicalTrials.gov NCT06673069

Updated Oct 3, 2026. Something wrong or missing? Report it on the IONS page.

Follow IONS, the company behind ION269

See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IONS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z